Watson J C, Hadler S C, Dykewicz C A, Reef S, Phillips L
MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57.
These revised recommendations of the Advisory Committee on Immunization Practices (ACIP) on measles, mumps, and rubella prevention supersede recommendations published in 1989 and 1990. This statement summarizes the goals and current strategies for measles, rubella, and congenital rubella syndrome (CRS) elimination and for mumps reduction in the United States. Changes from previous recommendations include: Emphasis on the use of combined MMR vaccine for most indications; A change in the recommended age for routine vaccination to 12-15 months for the first dose of MMR, and to 4-6 years for the second dose of MMR; A recommendation that all states take immediate steps to implement a two dose MMR requirement for school entry and any additional measures needed to ensure that all school-aged children are vaccinated with two doses of MMR by 2001; A clarification of the role of serologic screening to determine immunity; A change in the criteria for determining acceptable evidence of rubella immunity; A recommendation that all persons who work in health-care facilities have acceptable evidence of measles and rubella immunity; Changes in the recommended interval between administration of immune globulin and measles vaccination; and Updated information on adverse events and contraindications, particularly for persons with severe HIV infection, persons with a history of egg allergy or gelatin allergy, persons with a history of thrombocytopenia, and persons receiving steroid therapy.
免疫实践咨询委员会(ACIP)关于麻疹、腮腺炎和风疹预防的这些修订建议取代了1989年和1990年发布的建议。本声明总结了美国消除麻疹、风疹和先天性风疹综合征(CRS)以及减少腮腺炎的目标和当前策略。与先前建议的变化包括:强调在大多数情况下使用联合麻疹、腮腺炎和风疹疫苗(MMR);将常规接种的推荐年龄变更为:MMR第一剂为12至15个月,MMR第二剂为4至6岁;建议所有州立即采取措施,对入学实施两剂MMR要求以及采取任何其他必要措施,以确保到2001年所有学龄儿童都接种两剂MMR;澄清血清学筛查在确定免疫方面的作用;变更确定风疹免疫可接受证据的标准;建议所有在医疗保健机构工作的人员有麻疹和风疹免疫的可接受证据;变更免疫球蛋白与麻疹疫苗接种之间的推荐间隔;以及更新关于不良事件和禁忌证的信息,特别是针对严重HIV感染患者、有鸡蛋过敏或明胶过敏史的患者、有血小板减少症病史的患者以及接受类固醇治疗的患者。